ZTO Express Cayman (ZTO) Upgraded to Strong Buy: Here's What You Should Know — Positive
ZTO Zacks Investment Research — January 21, 2026ZTO Express Cayman (ZTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Dollar General (DG) a Strong Momentum Stock: Buy Now? — Positive
DG Zacks Investment Research — January 21, 2026Does Dollar General (DG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Rio Tinto (RIO) Is Up 4.93% in One Week: What You Should Know — Positive
RIO Zacks Investment Research — January 21, 2026Does Rio Tinto (RIO) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy — Positive
PRTA Zacks Investment Research — January 21, 2026Prothena (PRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aveanna (AVAH) Upgraded to Strong Buy: What Does It Mean for the Stock? — Positive
AVAH Zacks Investment Research — January 21, 2026Aveanna (AVAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Daktronics (DAKT) Upgraded to Strong Buy: Here's Why — Positive
DAKT Zacks Investment Research — January 21, 2026Daktronics (DAKT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Penske (PAG) Upgraded to Buy: Here's What You Should Know — Positive
PAG Zacks Investment Research — January 21, 2026Penske (PAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Did Nvidia's CEO Just Deliver the Ultimate Buy Signal for Nebius? — Positive
NBIS 24/7 Wall Street — January 21, 2026Nebius Group ( NASDAQ:NBIS ) is forecasting up to 1,600% revenue growth by the end of 2026, driven by surging demand for AI compute infrastructure.
TSMC (TSM) Is Up 5.80% in One Week: What You Should Know — Positive
TSM Zacks Investment Research — January 21, 2026Does TSMC (TSM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Credicorp (BAP) is a Great Momentum Stock to Buy — Positive
BAP Zacks Investment Research — January 21, 2026Does Credicorp (BAP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Carnival (CCL) Upgraded to Buy: Here's Why — Positive
CCL Zacks Investment Research — January 21, 2026Carnival (CCL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are You Looking for a Top Momentum Pick? Why Ciena (CIEN) is a Great Choice — Positive
CIEN Zacks Investment Research — January 21, 2026Does Ciena (CIEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nvidia (NVDA) Upgraded to Strong Buy: Here's Why — Positive
NVDA Zacks Investment Research — January 21, 2026Nvidia (NVDA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Astronics Corporation (ATRO) Is Up 12.94% in One Week: What You Should Know — Positive
ATRO Zacks Investment Research — January 21, 2026Does Astronics Corporation (ATRO) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About KORU Medical Systems, Inc. (KRMD) Rating Upgrade to Buy — Positive
KRMD Zacks Investment Research — January 21, 2026KORU Medical Systems, Inc. (KRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Marvell (MRVL) Upgraded to Buy: Here's What You Should Know — Positive
MRVL Zacks Investment Research — January 21, 2026Marvell (MRVL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AtaiBeckley seen as key beneficiary of Spravato's strong growth: Jefferies — Positive
ATAI Proactive Investors — January 21, 2026Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful tailwind for the broader psychedelics sector, with AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) a direct beneficiary. As reported by J&J on Wednesday, Spravato's fourth quarter 2025 sales in treatment-resistant depression (TRD) rose 10% sequentially to $503 million worldwide.
The Mag 7 is not performing, says @Theotrade's Don Kaufman, something he says investors need to watch in the sessions ahead as it could exhibit a sign of market weakness. As for today's Big 3, Don explains why he's bullish on Procter & Gamble (PG) while staying bearish on the SPDR S&P Regional Banking ETF (KRE) and eBay Inc. (EBAY).
ARDT Investors Have Opportunity to Lead Ardent Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm — Neutral
ARDT GlobeNewsWire — January 21, 2026LOS ANGELES, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardent Health, Inc. (“Ardent” or “the Company”) (NYSE: ARDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 9, 2026.
Holzer & Holzer, LLC Reminds Investors of the January 26, 2026 Lead Plaintiff Deadline in the Alexandria Real Estate Equities, Inc. (ARE) Securities Class Action – Investors With Significant Losses Encouraged to Contact the Firm — Neutral
ARE GlobeNewsWire — January 21, 2026ATLANTA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Alexandria's business, operations, and prospects, including allegations that, among other things, Defendants created the false impression that they possessed reliable information pertaining to the Company's leasing spreads, development tenant pipeline, and anticipated occupancy growth for its life-science properties, while also minimizing risk from macroeconomic fluctuations.
